Open AccessContinuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
Author(s) -
Inoue Yuichi,
Suzuki Hidenobu,
Hibino Hiroyuki,
Takaya Atsuhiko,
Mikami Katsunaka,
Yamamoto Kenji,
Matsumoto Hideo
Publication year - 2021
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.2109
Subject(s) - asenapine , medicine , clinical global impression , continuation , schizophrenia (object oriented programming) , psychiatry , antipsychotic , alternative medicine , pathology , computer science , programming language , placebo
Abstract Introduction The current study sought to compare the treatment continuation rates of asenapine and brexpiprazole while specifically investigating the factors influencing this index and the clinical efficacy of brexpiprazole. Methods Retrospective study on patients with schizophrenia who were prescribed either asenapine ( n = 73) or brexpiprazole ( n = 136), as part of their routine medical care. Results The treatment continuation rates for asenapine and brexpiprazole were 19.0% and 38.6% at 52 weeks, with that of brexpiprazole found to be significantly higher than that of asenapine ( p = .002). Moreover, age was found to be a significant factor affecting the treatment continuation rate for brexpiprazole ( p = .03). Additionally, patients with a longer continuation duration had significantly lower Clinical Global Impression‐Severity of Illness (CGI‐S) scale scores compared to those who discontinued early ( p = .04). The continuation rate was also significantly higher for those who began using the drug as outpatients compared to those first administered the drug as inpatients ( p = .04). Furthermore, disease duration, CGI‐S scale, and continuation duration significantly affected the clinical efficacy of brexipiprazole ( p < .05 for all). Conclusions The continuation rate for brexpiprazole increases as the age of the patient increases, as disease severity decreases, and if the patient first uses the drug as an outpatient. Shorter disease duration and longer drug administration may lead to improved clinical efficacy. These results suggest that brexpiprazole is an effective treatment option for maintenance therapy of schizophrenia.